Piper Sandler analyst Biren Amin maintained a Buy rating on Allogene Therapeutics (ALLO – Research Report) today and set a price target ...

Amin covers the Healthcare sector, focusing on stocks such as Ocular Therapeutix, Apellis Pharmaceuticals, and BridgeBio Pharma. The word on The Street in general, suggests a Strong Buy analyst ...

Apellis Pharmaceuticals (NASDAQ:APLS – Free Report) had its price target decreased by Bank of America from $61.00 to $47.00 ...

Peer Ratings Comparison In this comparison, we explore the analyst ratings and average 1-year price targets of Iovance Biotherapeutics, Apellis Pharmaceuticals and Amicus Therapeutics, three ...

In this comparison, we explore the analyst ratings and average 1-year price targets of Iovance Biotherapeutics, Apellis Pharmaceuticals and Amicus Therapeutics, three prominent industry players ...

The below comparison of the analyst ratings and average 1-year price targets of Iovance Biotherapeutics, Apellis Pharmaceuticals and Amicus Therapeutics, three prominent players in the industry ...

Kymera Therapeutics (NASDAQ:KYMR) is preparing to release its quarterly earnings on Thursday, 2024-10-31. Here's a brief overview of what investors should keep in mind before the announcement.

AUPH), Apellis Pharmaceuticals (NASDAQ: APLS), Checkmate Pharmaceuticals (NASDAQ: CMPI, acquired by Regeneron), Turning Point Therapeutics (NASDAQ: TPTX, acquired by BMS), Akero Therapeutics ...

On Monday, Citi reaffirmed its Buy rating on Apellis Pharmaceuticals (NASDAQ:APLS) stock with a steady price target of $63.00. The endorsement follows the company's presentation at the American ...

DUBLIN and CHICAGO, Oct. 25, 2024 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM) (Iterum), today announced that the U.S. Food and Drug Administration (FDA) has approved Iterum’s new ...

Viking Therapeutics (NASDAQ:VKTX) added ~18% on Thursday to reach a five-month high as Wall Street focused on updates on its obesity candidate VK2735, even as the company posted better-than ...